Ace Therapeutics introduces its specialized preclinical ophthalmic drug development services, designed to accelerate the discovery and development of novel therapies for eye diseases.
Ace Therapeutics, a premier preclinical CRO, announces its dedicated preclinical ophthalmic drug development services to help expedite the discovery and development of cutting-edge treatments for ocular diseases. At the core of innovation and compliance is Ace Therapeutics, which assists pharma and biotech firms to launch successful ophthalmic therapies.
Emerging areas include neuromodulation approaches leveraging visual cortex plasticity to compensate for retinal damage 3, and multi-omics validation of iPSC-RPE batches to ensure consistency. These preclinical advances collectively address critical barriers: bioavailability limitations, target specificity, and durable efficacy. As they move toward clinical translation, they promise to transform management of blinding diseases from symptomatic treatment to disease modification and restoration of vision.
CRISPR In Vivo Delivery: BD111 uses VLP mRNA/RNP delivery for HSV-1 keratitis treatment. A single intrastromal injection targets viral genomes in phase II trials, potentially eliminating latent virus to prevent recurrence, addressing a major unmet need where current antivirals fail 8.
Ocular Immunology Insights: Adaptive optics imaging reveals that microglia (not neutrophils) exclusively handle photoreceptor damage in the retina. This “immune cloaking” mechanism protects neural tissue from inflammatory cascades, informing safer immunomodulatory strategies
The development of drugs for the treatment of ocular diseases is accompanied by several hurdles such as the anatomical and physiological complexity of the eye, the massive regulatory demands, and the importance of targeted drug delivery. But advances in drug delivery, biologics, and gene therapy are creating opportunities for improved treatments. As an experienced provider of preclinical ophthalmology CRO services, Ace Therapeutics offers end-to-end preclinical services tailored to ophthalmic drug development, including:
- Disease modeling for conditions such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, dry eye disease, and uveitis.
- Pharmacokinetics (PK) and pharmacodynamics (PD) studies to assess drug absorption, distribution, and efficacy in ocular tissues.
- Toxicology and safety evaluations to ensure compliance with FDA, EMA, and other regulatory guidelines.
- Formulation optimization for topical, intravitreal, and sustained-release drug delivery systems.
- Biomarker identification and efficacy testing using advanced in vitro and in vivo models.
Ace Therapeutics’ Cutting-Edge Expertise in Ophthalmology
Supported by experienced scientists and with in-house state-of-the-art facilities, Ace Therapeutics uses advanced ocular disease models and translational research to reduce attrition between preclinical and clinical success. Its capabilities cover small and large compounds, gene therapies, and new drug delivery systems.
“Ophthalmic indications pose a variety of drug development challenges, from bioavailability to targeted delivery,” added the business development manager at Ace Therapeutics. “Our preclinical ophthalmic capabilities are all about delivering robust and high-quality data that de-risks development and speeds the road to IND acceptance.”
“We provide ophthalmology drug testing services to evaluate the efficacy of your drug candidates. Our customized in vivo ocular disease models and comprehensive ocular dosing services are designed to conduct in vivo ocular drug studies and evaluate your ophthalmic products. Specializing in ophthalmic biomarker development, we offer comprehensive solutions tailored to your research needs. Our expertise covers discovery, screening, identification, analysis, and translation of biomarkers, supporting decision-making and reducing project development risk.”
Ace Therapeutics collaborates with biopharmaceutical companies worldwide to advance next-generation ophthalmic treatments. By integrating customized study designs, advanced imaging technologies, and regulatory support, the company helps clients optimize their candidates for clinical trials. For more information on Ace Therapeutics’ preclinical ophthalmic drug development services, visit www.acetherapeutics.com/ophthalmology.
About Ace Therapeutics
Ace Therapeutics is a research service provider specializing in ophthalmology. It provides researchers around the globe with comprehensive solutions for ophthalmic drug discovery and preclinical development. Backend with scientific expertise and cutting-edge equipment, Ace Therapeutics’ services span in vivo ocular efficacy studies, bioanalysis, and various preclinical studies designed to support the development of ophthalmic drugs.
Leave a comment